Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at :

NCT ID NCT04470674
Title Study of Durvalumab or Durvalumab Plus Chemotherapy in Kras Mutation Positive and PD-L1 High (>=50%) NSCLC Patients
Recruitment Withdrawn
Gender both
Phase Phase II
Variant Requirements No
Sponsors Shirish M Gadgeel

lung non-squamous non-small cell carcinoma


Carboplatin + Durvalumab + Pemetrexed Disodium

Durvalumab + Pemetrexed Disodium


Age Groups: adult | senior
Covered Countries USA

No variant requirements are available.